CICERO, ARRIGO FRANCESCO GIUSEPPE
 Distribuzione geografica
Continente #
EU - Europa 34.081
NA - Nord America 29.206
AS - Asia 27.175
SA - Sud America 2.449
AF - Africa 1.306
OC - Oceania 188
Continente sconosciuto - Info sul continente non disponibili 16
Totale 94.421
Nazione #
US - Stati Uniti d'America 28.888
IT - Italia 16.602
CN - Cina 8.040
SG - Singapore 7.931
GB - Regno Unito 5.645
VN - Vietnam 4.892
DE - Germania 3.555
HK - Hong Kong 2.056
BR - Brasile 1.839
IN - India 1.617
RU - Federazione Russa 1.289
SE - Svezia 1.279
UA - Ucraina 1.159
KR - Corea 1.083
NL - Olanda 1.050
FR - Francia 961
IE - Irlanda 738
ZA - Sudafrica 529
JP - Giappone 394
EE - Estonia 381
CI - Costa d'Avorio 296
CH - Svizzera 258
AR - Argentina 242
ID - Indonesia 228
FI - Finlandia 184
AU - Australia 170
SC - Seychelles 162
TG - Togo 157
CA - Canada 154
AT - Austria 149
JO - Giordania 135
TR - Turchia 127
MX - Messico 126
PL - Polonia 124
BG - Bulgaria 122
EC - Ecuador 119
BE - Belgio 110
GR - Grecia 108
ES - Italia 90
IR - Iran 89
BD - Bangladesh 76
PK - Pakistan 75
IQ - Iraq 70
CL - Cile 65
PE - Perù 61
CO - Colombia 55
MY - Malesia 54
EG - Egitto 44
RO - Romania 43
TW - Taiwan 38
LB - Libano 36
AL - Albania 33
AE - Emirati Arabi Uniti 32
PY - Paraguay 32
PH - Filippine 31
NG - Nigeria 29
TH - Thailandia 26
RS - Serbia 22
HR - Croazia 21
CZ - Repubblica Ceca 18
NZ - Nuova Zelanda 18
PT - Portogallo 18
UZ - Uzbekistan 18
VE - Venezuela 18
KE - Kenya 17
KZ - Kazakistan 17
LT - Lituania 16
LU - Lussemburgo 16
NP - Nepal 16
MA - Marocco 15
NO - Norvegia 15
SA - Arabia Saudita 15
DO - Repubblica Dominicana 14
HU - Ungheria 14
SK - Slovacchia (Repubblica Slovacca) 13
UY - Uruguay 13
AZ - Azerbaigian 12
IL - Israele 11
LK - Sri Lanka 11
TN - Tunisia 11
EU - Europa 8
LV - Lettonia 8
MC - Monaco 8
SN - Senegal 8
DZ - Algeria 7
DK - Danimarca 6
OM - Oman 6
SI - Slovenia 6
A2 - ???statistics.table.value.countryCode.A2??? 5
BY - Bielorussia 5
KW - Kuwait 5
MT - Malta 5
AM - Armenia 4
BO - Bolivia 4
ET - Etiopia 4
GE - Georgia 4
KH - Cambogia 4
MN - Mongolia 4
SV - El Salvador 4
AO - Angola 3
Totale 94.345
Città #
Singapore 5.030
Southend 4.932
Fairfield 3.494
Hefei 2.536
Ashburn 2.448
Hong Kong 2.002
Woodbridge 1.729
Chandler 1.709
Wilmington 1.567
Milan 1.541
Seattle 1.518
Princeton 1.403
Houston 1.391
Santa Clara 1.315
Cambridge 1.195
Rome 1.118
Ho Chi Minh City 1.097
Dong Ket 1.055
Seoul 1.025
Boardman 898
Ann Arbor 851
Bologna 798
Hanoi 794
Beijing 772
Dublin 715
Jacksonville 680
Westminster 537
Padova 533
Nanjing 501
Turin 449
Los Angeles 433
Naples 407
Berlin 382
Tokyo 373
Buffalo 320
Abidjan 296
Florence 276
Dallas 263
Saint Petersburg 257
Bengaluru 249
Bremen 242
Redondo Beach 240
San Diego 239
Jinan 221
Shenyang 204
São Paulo 189
Düsseldorf 180
Palermo 167
Bari 166
Nanchang 162
Lomé 157
Mülheim 147
Verona 142
Changsha 141
Hebei 139
Shanghai 138
Amman 134
Des Moines 125
Tianjin 122
Catania 120
Guangzhou 119
Medford 119
Sofia 116
Jakarta 112
New York 112
The Dalles 112
Chicago 111
Genoa 109
Parma 109
Haiphong 107
Dearborn 103
Yubileyny 100
Helsinki 99
San Venanzo 96
Brescia 95
Da Nang 93
Nuremberg 92
Olalla 90
Bern 89
Norwalk 87
Zhengzhou 87
Brussels 86
Jiaxing 84
Mahé 81
Redwood City 79
Frankfurt am Main 77
Modena 77
Redmond 75
London 74
Pescara 71
Falls Church 69
Ningbo 69
Vienna 67
Cagliari 65
Ha Long 65
Hải Dương 65
Tongling 65
Rio de Janeiro 64
Biên Hòa 63
Hangzhou 61
Totale 55.778
Nome #
La fame d’amore: un bambino che sta bene non piange. 12.204
Regressione completa di xantelasmi palpebrali in seguito a prolungatra terapia con statine: Case Report 1.672
Combined action of SAMe, Folate, and Vitamin B12 in the treatment of mood disorders: a review. 1.196
Lo studio Brisighella: 40 anni di ricerca nella prevenzione delle malattie cardiovascolari. 1.106
Short-term evolocumab-induced tendon xanthomas regression in an elderly patient with homozygous familial hypercholesterolemia 568
I lactotripeptidi IPP e VPP riducono la pressione arteriosa sistolicanei soggetti europei? Una metaanlisi degli studi randomizzati controllati. 448
Capacità di efflusso del colesterolo e rigidità arteriosa nei soggetti sani: i dati del Brisighella Heart Study. 329
Miglioramento dell'hepatic steatosi index in pazienti dislipidemici ed in sovrappeso trattati con nutraceutici ipolipemizzanti. 327
Pharmanutrition and Functional food 282
A meta-analysis of Italian and Estonian individuals shows an effect of common variants in HMGCR on blood apoB levels 241
Is the 2020 Sampson equation the best formula for LDL-C estimation? 237
Serum uric acid, predicts heart failure in a large Italian cohort: search for a cut-off value the URic acid Right for heArt Health study 226
Bioactive peptides in cereals and legumes: agronomical, biochemical and clinical aspects. 223
Hepatitis C virus recurrence after liver transplantation: a 10-year evaluation. 195
Is it Possible to Significantly Modify Blood Pressure with a Combined Nutraceutical on Top of a Healthy Diet? The Results of a Pilot Clinical Trial 195
Effects of Siberian ginseng (Eleutherococcus senticosus maxim.) on elderly quality of life: a randomized clinical trial. 191
A nutraceutical approach (Armolipid Plus) to reduce total and LDL cholesterol in individuals with mild to moderate dyslipidemia: Review of the clinical evidence 191
Serum uric acid predicts incident metabolic syndrome in the elderly in an analysis of the Brisighella Heart Study 189
Cardiovascular risk factors and hearing impairment: a non-automatic correlation 188
Effect of apple polyphenols on vascular oxidative stress and endothelium function: A translational study 188
Wath are the major risk factors for type II diabetes development in the historical cohort of the Brisighella heart study? A 16-years follow-up 186
Sex X Time Interactions in Lp(a) and LDL-C Response to Evolocumab 183
Cost-effectiveness of zofenopril in patients with left ventricular systolic dysfunction after acute myocardial infarction: a post hoc analysis of SMILE-4. 181
Effect of Dietary Supplementation with Eufortyn® Colesterolo Plus on Serum Lipids, Endothelial Reactivity, Indexes of Non-Alcoholic Fatty Liver Disease and Systemic Inflammation in Healthy Subjects with Polygenic Hypercholesterolemia: The ANEMONE Study. Nutrients. 2022 May 18;14(10):209 176
Progress towards 3D bioprinting of tissue models for advanced drug screening: In vitro evaluation of drug toxicity and drug metabolism 175
Differential effect of glimepiride and rosiglitazone on metabolic control of type 2 diabetic patients treated with metformin: a randomized, double-blind, clinical trial. 175
n-3 Polynsatured fatty acids and the patient at high cardiovascular risk with co-morbidities: a pleiotropic drug. 175
Treatment of massive hypertriglyceridemia resistant to PUFA and fibrates: a possible role for the coenzyme Q10? 172
Antithrombotic effects of rosiglitazone-metformin versus glimepiride-metformin combination therapy in patients with type 2 diabetes mellitus and metabolic syndrome. 170
Epidemiologia delle malattie cerebrovascolari. 169
Possible role of ubiquinone in the treatment of massive hypertriglyceridemia resistant to PUFA and fibrates. 168
1A.11: ASSOCIATION OF KIF6 AND HMGCR LOCI WITH CARDIOMETABOLIC PHENOTYPES AND RESPONSE TO STATIN THERAPY IN THE BRISIGHELLA COHORT 167
Short-Term Hemodynamic Effects of Modern Wheat Products Substitution in Diet with Ancient Wheat Products: A Cross-Over, Randomized Clinical Trial 167
Dietary integration with chondroitin sulfate/glucosamine hydrochloride on osteoarthritis: a critical review of available evidence. 165
Prevalence and the relative role of the main predictors of metabolic syndrome development in the hystorical cohort of the Brisighella heart study: 16-years follow-up 165
Changes in LDL fatty acid composition as a response to olive oil treatment are inversely related with the lipid oxidative damage: the EUROLIVE Study. 165
Relationship between lipid phenotypes, overweight, lipid lowering drug response and KIF6 and HMG-CoA genotypes in a subset of the brisighella heart study population 164
A Randomized Placebo-Controlled Clinical Trial to Evaluate the Medium-Term Effects of Oat Fibers on Human Health: The Beta-Glucan Effects on Lipid Profile, Glycemia and inTestinal Health (BELT) Study 164
Effects of a new low dose soy protein β-sitosterol association on plasma lipid levels and oxidation 163
A comparison study of Lp(a) plasma levels distributions between normo- and hypertensive subjects with high BMI. 163
The ferrari corporate wellness program: a new concept of cardiovascular prevention in the compagnie 163
Arterial stiffness, sugar-sweetened beverages and fruits intake in a rural population sample: Data from the brisighella heart study 163
Changes in peak systolic velocity induced by chronic therapy with phosphodiesterase type 5 inhibitor. 162
A comparison of the effects of pioglitazone and rosiglitazone combined with glimepiride on prothrombotic state in type 2 diabetic patients with the metabolic syndrome. 162
Long-term effect of glimepiride and rosiglitazone on non-conventional cardiovascular risk factors in metformin-treated patients affected by metabolic syndrome: a randomized, double-blind clinical trial. 161
Novel role of the nutraceutical bioactive compound Berberine in lectin-like OxLDL receptor 1 -mediated endothelial dysfunction in comparison to Lovastatin 161
Effects of n-3 PUFAs on postprandial variation of metalloproteinases, and inflammatory and insulin resistance parameters in dyslipidemic patients: evaluation with euglycemic clamp and oral fat load. 160
Sources of variabilità of plasma HDL-cholesterol levels. 159
Nutraceutici ed alimenti funzionali in medicina preventiva. 159
Effect of spontaneous changes in dietary components and lipoprotein(a) levels: Data from the Brisighella Heart Study 157
Red Yeast Rice for Hypercholesterolemia: JACC Focus Seminar 157
Berberine: metabolic and cardiovascular effects in preclinical and clinical trials. 156
Dal farmaco di ricerca al farmaco equivalente. 156
Canrenone on cardiovascular mortality in congestive heart failure: CanrenOne eFFects on cardiovascular mortality in patiEnts with congEstIve hearT failure: The COFFEE-IT study 156
Black Garlic and Pomegranate Standardized Extracts for Blood Pressure Improvement: A Non-Randomized Diet-Controlled Study. 155
Relative role of major risk factors for Type 2 Diabetes development in the historical cohort of the Brisighella Heart Study: an 8-years follow-up. 155
Adipokines and sexual hormones associated with the components of the metabolic syndrome in pharmacologically untreated subjects: data from the Brisighella Heart Study. 155
Software per l'identificazione automatica delle iperlipoproteinemie genetiche 154
Combined lipoxygenase/cyclo-oxygenase inhibition in the elderly: the example of licofelone. 153
Profile of evolocumab and its potential in the treatment of hyperlipidemia 153
Immune modulation by curcumin: The role of interleukin-10. 152
REVERSAL and PROVE-IT: are clinically oriented trials really better than "pure" scientific studies? 151
Effects of nateglinide and glibenclamide on prothrombotic factors in naïve type 2 diabetic patients treated with metformin: a 1-year, double-blind, randomized clinical trial. 151
Effect of red yeast rice combined with antioxidants on lipid pattern, hs-CRP level, and endothelial function in moderately hypercholesterolemic subjects. 151
An evidence-based review on urate-lowering treatments: Implications for optimal treatment of chronic hyperuricemia 151
Ruolo di lacidipina nel paziente iperteso 150
Acarbose actions on insulin resistance and inflammatory parameters during an oral fat load. 150
Relazione tra livelli sierici di acido urico e rigidità arteriosa in un campione di adulti-anziani: i dati del Brisighella Heart Study 150
Metabolic Syndrome prevalence in Italy. 149
Nutraceutical approach to Non-alcoholic fatty liver disease (NAFLD): the available clinical evidence. 149
Efficacia della supplementazione dietetice con fibre solubili nelle gestione del rischio delle malattie cardiovascolari di pazienti affetti da SM: un trial clinico randomizzato open label di un anno 147
Prevalence of metabolic syndrome in working population: preliminary results fo a campaign of cardiovascular risk screening 146
High serum uric acid is associated to poorly controlled blood pressure and higher arterial stiffness in hypertensive subjects 146
Prevalenza e determinati clinico-laboratoristici della sindrome metabolica in un campione di soggetti in età geriatrica: il Brisighella Heart Study 145
Effetto della supplementazione cronica in fibre solubili sul controllo pressorio e ponderale di soggetti ipertesi e in sovrappeso: uno studio randomizzato, open-label, di 6 mesi. 145
Awareness of major cardiovascular risk factors and its relationship with markers of vascular aging: data from the Brisighella Heart Study 145
Farmaci ipocolesterolemizzanti. 144
Candesartan effect on inflammation in hypertension. 144
Comparison of fluvastatin + fenofibrate combination therapy and fluvastatin monotherapy in the treatment of combined hyperlipidemia, type 2 diabetes mellitus, and coronary heart disease: a 12-month, randomized, double-blind, controlled trial. 144
Antidiabetic properties of berberine: from cellular pharmacology to clinical effects. 144
Morbidity and mortality in a population of patients affected by heart failure and chronic obstructive pulmonary disease: an observational study. 144
Association between not HDL cholesterol levels and hypertension in the Brisighella Hart Study. 143
Comparison between orlistat plus l-carnitine and orlistat alone on inflammation parameters in obese diabetic patients. 143
Matrix metalloproteinase-2, -9, and tissue inhibitor of metalloproteinase-1 in patients with hypertension. 142
Effects of lactotripeptides assumed as functional food on office and 24-hour blood pressure, stress-induced blood pressure increase, pulse wave velocity and cardiac output related parameters: a rondomized, double-blindd, clinical trial. 142
Comparison between metalloproteinases-2 and -9 in healthy subjects, diabetics, and subjects with acute coronary syndrome. 141
2B02: SERUM URIC ACID LEVEL, BUT NOT RENAL FUNCTION OR ARTERIAL STIFFNESS, IS ASSOCIATED TO WORSE BLOOD PRESSURE CONTROL IN GENERAL PRACTICE: DATA FROM THE BRISIGHELLA HEART STUDY 141
Serum uric acid change and modification of blood pressure and fasting plasma glucose in an overall healthy population sample: data from the Brisighella heart study 141
Amount of physical activity in middle-age hypertensive patients. 140
Comparison Between a Single-Lead ECG Garment Device and a Holter Monitor: A Signal Quality Assessment 139
Self-Reported Coffee Consumption and Central and Peripheral Blood Pressure in the Cohort of the Brisighella Heart Study. 139
Adverse reactions related to drugs for headache treatment: clinical impact. 139
Variation of some inflammatory markers in hypertensive patients after 1 year of olmesartan/amlodipine single-pill combination compared with olmesartan or amlodipine monotherapies. 139
Iperlipoproteinemia familiare combinata: complicanze cardiovascolari e cerebrovascolari 138
Cocoa bioactive compounds: significance and potential for the maintenance of skin health. 138
Fatty liver index is associated to pulse wave velocity in healthy subjects: Data from the Brisighella Heart Study 138
Effects of a standardized oral fat load on vascular remodelling markers in healthy subjects. 137
Treatment with PCSK9 Inhibitor Evolocumab Improves Vascular Oxidative Stress and Arterial Stiffness in Hypercholesterolemic Patients with High Cardiovascular Risk 136
Need for analgesics/drugs of abuse: a comparison between headache patients and addicts by the Leeds Dependence Questionnaire (LDQ). 136
Dislipidemia e coronaropatia. 135
Totale 32.711
Categoria #
all - tutte 253.593
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 253.593


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/20214.930 0 0 0 0 0 337 180 487 881 477 412 2.156
2021/20229.845 897 307 641 563 1.075 683 204 876 467 363 1.956 1.813
2022/202310.199 1.190 1.184 442 1.381 651 589 474 718 1.622 490 945 513
2023/20246.489 246 602 379 395 431 457 459 458 421 896 803 942
2024/202522.373 1.236 3.183 1.982 1.731 2.940 1.401 2.043 1.046 808 1.189 1.324 3.490
2025/202620.869 3.310 5.404 4.172 3.456 3.416 1.111 0 0 0 0 0 0
Totale 96.257